246 related articles for article (PubMed ID: 17996595)
1. Immune therapies.
Prabhala RH; Munshi NC
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1217-30, x-xi. PubMed ID: 17996595
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells in clinical trials for multiple myeloma.
Reichardt VL; Brossart P
Methods Mol Med; 2005; 109():127-36. PubMed ID: 15585918
[TBL] [Abstract][Full Text] [Related]
3. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
[TBL] [Abstract][Full Text] [Related]
4. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
Guardino AE; Rajapaksa R; Ong KH; Sheehan K; Levy R
Cytotherapy; 2006; 8(3):277-89. PubMed ID: 16793736
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
9. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
10. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
[TBL] [Abstract][Full Text] [Related]
11. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
[TBL] [Abstract][Full Text] [Related]
12. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
13. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Wen YJ; Barlogie B; Yi Q
Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117
[TBL] [Abstract][Full Text] [Related]
14. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Yi Q; Szmania S; Freeman J; Qian J; Rosen NA; Viswamitra S; Cottler-Fox M; Barlogie B; Tricot G; van Rhee F
Br J Haematol; 2010 Sep; 150(5):554-64. PubMed ID: 20618329
[TBL] [Abstract][Full Text] [Related]
15. [The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells].
Ocadlíková D; Zahradová L; Kovárová L; Smejkalová J; Pour L; Vidláková P; Kyjovská D; Moravcová J; Rycová M; Novotná H; Jelínková I; Penka M; Michálek J; Hájek R
Klin Onkol; 2009; 22(2):67-72. PubMed ID: 19522376
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.
Hart DN; Hill GR
Immunol Cell Biol; 1999 Oct; 77(5):451-9. PubMed ID: 10540212
[TBL] [Abstract][Full Text] [Related]
17. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
Lim SH; Bailey-Wood R
Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
[TBL] [Abstract][Full Text] [Related]
18. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
Rhee Fv
Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
[No Abstract] [Full Text] [Related]
19. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
Hollander N
Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
[TBL] [Abstract][Full Text] [Related]
20. Preparing the ground for vaccination against multiple myeloma.
Stevenson FK; Anderson KC
Immunol Today; 2000 Apr; 21(4):170-1. PubMed ID: 10798849
[No Abstract] [Full Text] [Related]
[Next] [New Search]